Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| 1 |
Apple
AAPL
|
$1.44B |
| 2 |
Microsoft
MSFT
|
$1.16B |
| 3 |
Amazon
AMZN
|
$797M |
| 4 |
Tesla
TSLA
|
$537M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
$441M |
Top Sells
| 1 |
XLNX
Xilinx Inc
XLNX
|
$199M |
| 2 |
INFO
IHS Markit Ltd. Common Shares
INFO
|
$191M |
| 3 |
NUAN
Nuance Communications, Inc.
NUAN
|
$62.8M |
| 4 |
KL
Kirkland Lake Gold Ltd Ordinary
KL
|
$43.9M |
| 5 |
ATH
Athene Holding Ltd. Class A Common Shares
ATH
|
$42.6M |
Sector Composition
| 1 | Technology | 28.24% |
| 2 | Healthcare | 14.22% |
| 3 | Consumer Discretionary | 13.07% |
| 4 | Communication Services | 9.52% |
| 5 | Industrials | 8.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2651
Alaunos Therapeutics
TCRT
$4.21M
| $333K | ﹤0.01% | 511,120 +38,800 | +8% | +$25.3K |
|
|
TRHC
2652
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
| $333K | ﹤0.01% | 57,800 +5,700 | +11% | +$32.8K |
|
|
RMO
2653
DELISTED
Romeo Power, Inc.
RMO
| $331K | ﹤0.01% | 222,100 +19,100 | +9% | +$28.5K |
|
2654
Cue Biopharma
CUE
$60M
| $330K | ﹤0.01% | 67,600 +5,100 | +8% | +$24.9K |
|
2655
ALX Oncology
ALXO
$62.7M
| $324K | ﹤0.01% | 19,200 +1,500 | +8% | +$25.3K |
|
2656
Oric Pharmaceuticals
ORIC
$994M
| $324K | ﹤0.01% | 60,600 +4,300 | +8% | +$23K |
|
2657
Sight Sciences
SGHT
$213M
| $324K | ﹤0.01% | 28,000 +1,900 | +7% | +$22K |
|
2658
Riskified
RSKD
$748M
| $320K | ﹤0.01% | 53,000 +10,300 | +24% | +$62.2K |
|
|
BGRY
2659
DELISTED
Berkshire Grey, Inc. Class A Common Stock
BGRY
| $305K | ﹤0.01% | 105,900 +7,900 | +8% | +$22.8K |
|
2660
Lexicon Pharmaceuticals
LXRX
$400M
| $294K | ﹤0.01% | 140,800 +13,500 | +11% | +$28.2K |
|
|
KRON
2661
DELISTED
Kronos Bio
KRON
| $289K | ﹤0.01% | 40,000 +2,900 | +8% | +$21K |
|
2662
Nkarta
NKTX
$151M
| $289K | ﹤0.01% | 25,400 | – | – |
|
2663
Akebia Therapeutics
AKBA
$833M
| $282K | ﹤0.01% | 393,085 +28,300 | +8% | +$20.3K |
|
|
KNTE
2664
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $270K | ﹤0.01% | 24,000 | – | – |
|
2665
Taysha Gene Therapies
TSHA
$797M
| $267K | ﹤0.01% | 41,000 +3,500 | +9% | +$22.8K |
|
2666
Atea Pharmaceuticals
AVIR
$267M
| $264K | ﹤0.01% | 36,500 | – | – |
|
2667
Q32 Bio
QTTB
$20.9M
| $256K | ﹤0.01% | 84,100 | – | – |
|
2668
BioAtla
BCAB
$26.7M
| $251K | ﹤0.01% | 50,200 +7,600 | +18% | +$38K |
|
|
VIEW
2669
DELISTED
View, Inc. Class A Common Stock
VIEW
| $236K | ﹤0.01% | 128,300 +8,800 | +7% | +$16.2K |
|
2670
SkyWater Technology
SKYT
$578M
| $233K | ﹤0.01% | 21,500 | – | – |
|
2671
Quince Therapeutics
QNCX
$85.9M
| $222K | ﹤0.01% | 35,800 | – | – |
|
|
LOTZ
2672
DELISTED
CarLotz, Inc. Class A Common Stock
LOTZ
| $222K | ﹤0.01% | 161,700 +11,400 | +8% | +$15.7K |
|
|
MILE
2673
DELISTED
Metromile, Inc. Common Stock
MILE
| $220K | ﹤0.01% | 166,700 | – | – |
|
2674
Spire Global
SPIR
$281M
| $216K | ﹤0.01% | 103,000 | – | – |
|
2675
Pliant Therapeutics
PLRX
$101M
| $209K | ﹤0.01% | 29,800 +2,400 | +9% | +$16.8K |
|